Cover Image
Market Research Report
Product code 
785758

U.S. Transthyretin Amyloidosis Treatment Market - Size, Share, Trends, and Forecast to 2026

Published: | Coherent Market Insights | 116 Pages | Delivery time: 2-3 business days

Price

Back to Top
U.S. Transthyretin Amyloidosis Treatment Market - Size, Share, Trends, and Forecast to 2026
Published: July 9, 2018
Coherent Market Insights
Content info: 116 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

The current treatment options of transthyretin amyloidosis majorly revolve around relieving patients from symptoms associated with the condition, and treating the underlying cause with a liver transplant. Drugs such as Tafamidis (not approved in the U.S.) and Diflunisal, help in stabilizing the transthyretin tetramer and are majorly used in the treatment of familial amyloid polyneuropathy (FAP). Tafamidis (manufactured by Pfizer, Inc.) is currently in the phase 3 clinical trials in the U.S. Supporting therapies include treatments for heart diseases associated with cardiomyopathy as well as for neuropathy, depending on the severity of the symptoms

Diagnosis of transthyretin amyloidosis is carried out in various ways such as imaging, histopathology, and molecular and genetic testing. Cardiac biomarkers such as NT-proBNP (N-terminal fragment of brain natriuretic peptide) and troponin are present in abnormally high concentrations in the heart, following amyloid deposits that can be tested for disease diagnosis. In case of diagnosis of familial transthyretin amyloidosis, genetic testing for transthyretin gene mutations is carried out.

Market Dynamics

Absence of the U.S. Food & Drug Administration (FDA) approved therapies for transthyretin amyloidosis is expected to be a major factor responsible for growth of drugs in the pipeline such as Patisiran and Inotersen (expected to receive approval in 2018). The market is expected to exhibit exponential growth, owing to rapid uptake of approved therapies.

Various other drugs in the pipeline besides Patisiran and Inotersen, such as Tafamidis and ALN-TTRsc02 are expected to boost growth of the market in the near future. These therapies in the pipeline are meant to treat the underlying cause of the disease, which is expected to be a major factor for the previously untreated disease that lacks availability of robust therapy.

Key features of the study:

This report provides in-depth analysis of the U.S. transthyretin amyloidosis treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026)

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the U.S. transthyretin amyloidosis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key companies covered as a part of this study include Alnylam Pharmaceuticals, Inc., Pfizer, Inc., Prothena Corporation Plc, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Inc., Eidos Therapeutics, and SOM Innovation Biotech, S.L.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The U.S. transthyretin amyloidosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the transthyretin amyloidosis treatment market

Detailed Segmentation:

  • U.S. Transthyretin Amyloidosis Treatment Market, By Drug:
  • Tafamidis
  • Diflunisal
  • Patisiran
  • Inotersen
  • Others
  • U.S. Transthyretin Amyloidosis Treatment Market, By Disease Type:
  • Hereditary Transthyretin Amyloidosis
  • Polyneuropathy
  • Cardiomyopathy
  • Mixed Type
  • Wild Type Amyloidosis
  • U.S. Transthyretin Amyloidosis Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Company Profiles
  • Alnylam Pharmaceuticals, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Pfizer, Inc.
  • Prothena Corporation Plc
  • Teva Pharmaceutical Industries Ltd.
  • Becton, Dickinson, and Company
  • Fresenius Kabi AG
  • “*” marked represents similar segmentation in other categories in the respective section.
Table of Contents

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Clinical Characteristics
  • Disease Diagnosis
  • Epidemiology
  • Transthyretin Amyloidosis Treatment Overview
  • PEST Analysis
  • PORTER's Analysis
  • Therapy Study (Mechanism of Action)

4. U.S. Transthyretin Amyloidosis Treatment Market, By Drug, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Tafamidis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Diflunisal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Patisiran
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Inotersen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

5. U.S. Transthyretin Amyloidosis Treatment Market, By Disease Type, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hereditary Transthyretin Amyloidosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
    • Polyneuropathy
    • Cardiomyopathy
    • Mixed Type
  • Wild Type Amyloidosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. U.S. Transthyretin Amyloidosis Treatment Market, By Distribution Channel, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Competitive Landscape

  • Company Profiles
    • Alnylam Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Prothena Corporation Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eidos Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • SOM Innovation Biotech, S.L.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact